Clinical Trial Update: PD1 and PARP for Maintenance Therapy in NSLLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating PD-1 and PARP inhibitors as maintenance therapy for lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• PARP inhibitor
• PD-1 inhibitor

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Lung Cancer | Phase 2 | Status: UNKNOWN